Publications

1. Death: The Simple Clinical Trial Endpoint.

Eisenstein EL, Prather K, Greene SJ, Harding T, Harrington A, Gabriel D, Jones I, Mentz RJ, Velazquez EJ, Anstrom KJ.

Stud Health Technol Inform. 2019;257:86-91.

2. Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?

Greene SJ, Mentz RJ.

Eur J Heart Fail. 2018 Mar;20(3):471-473. doi: 10.1002/ejhf.1024. Epub 2017 Oct 29. No abstract available.

3. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).

Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM.

Am J Cardiol. 2016 Feb 1;117(3):404-11. doi: 10.1016/j.amjcard.2015.10.059. Epub 2015 Nov 18.

4. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM.

Future Cardiol. 2015 Sep;11(5):585-95. doi: 10.2217/fca.15.56. Epub 2015 Sep 25.

5. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, OʼConnor CM, Velazquez EJ.

J Cardiovasc Pharmacol. 2015 May;65(5):438-43. doi: 10.1097/FJC.0000000000000212.

6. A reappraisal of loop diuretic choice in heart failure patients.

Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM.

Am Heart J. 2015 Mar;169(3):323-33. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6. Review.